Cited by 1,192Diabetes Treatment and ManagementDiabetes Management and ResearchHeart Failure Treatment and Management

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Open access

Buse, John B., Wexler, Deborah J., Tsapas, Apostolos, Rossing, Peter, Mingrone, Geltrude, Mathieu, Chantal, D’Alessio, David A., Davies, Melanie J.·2020·Diabetes Care

DOI 10.2337/dci19-0066PMC PMC6971782

Open this paper in CoChat — free account Open PDF

Abstract

The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualized HbA1c target; 2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and 3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min–1 [1.73 m]–2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2337/dci19-0066

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD)
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citation
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 1×
“Somemeta-analyses (5,13,14) suggest the presence of heterogeneity in estimates forMACE andCVdeathwithGLP-1 receptor agonists, although this ismostly due to the results of a single trial with lixisenatide.”
Result
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Self-citation
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084

Show all 21 references

Sorted by citations

2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association
Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021) · Stroke · doi:10.1161/str.0000000000000375 · Cited by 3,237
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citation
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Self-citation
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Self-citation
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)
Tanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., Ouatu, A., & Floria, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3920196 · Cited by 627
Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice
Yoon, H. S., Cho, C. H., Yun, M. S., Jang, S. J., You, H. J., Kim, J.-H., Han, D., Cha, K. H., Moon, S. H., Lee, K., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00880-5 · Cited by 602
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs
Artasensi, A., Pedretti, A., Vistoli, G., & Fumagalli, L. (2020) · Molecules · doi:10.3390/molecules25081987 · Cited by 540
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M., Morris, P. B., Neumiller, J. J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.037 · Cited by 466
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Ma, C.-X., Ma, X.-N., Guan, C.-H., Li, Y.-D., Mauricio, D., & Fu, S.-B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01516-6 · Cited by 464
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis
Tsapas, A., Avgerinos, I., Karagiannis, T., Malandris, K., Manolopoulos, A., Andreadis, P., Liakos, A., Matthews, D. R., & Bekiari, E. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0864 · Cited by 346
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
Kadowaki, T., Isendahl, J., Khalid, U., Lee, S. Y., Nishida, T., Ogawa, W., Tobe, K., Yamauchi, T., & Lim, S. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00008-0 · Cited by 330
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Li, R., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., & Guo, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1087260 · Cited by 347
Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel
Buzzetti, R., Tuomi, T., Mauricio, D., Pietropaolo, M., Zhou, Z., Pozzilli, P., & Leslie, R. D. (2020) · Diabetes · doi:10.2337/dbi20-0017 · Cited by 305
Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
Neuen, B. L., Oshima, M., Agarwal, R., Arnott, C. G., Cherney, D. Z. I., Edwards, R., Langkilde, A. M., Mahaffey, K. W., McGuire, D. K., Neal, B., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.057736 · Cited by 306
Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
Yun, J.-S., & Ko, S.-H. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154838 · Cited by 292
Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.024 · Cited by 278
Self-citation
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries
Mosenzon, O., Alguwaihes, A. M., Leon, J. L. A., Bayram, F., Darmon, P., Davis, T. M. E., Dieuzeide, G., Eriksen, K. T., Hong, T., Kaltoft, M. S., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01344-0 · Cited by 259
Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations
Ke, C., Narayan, K. M. V., Chan, J. C. N., Jha, P., & Shah, B. R. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00669-4 · Cited by 263
The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk
Caussy, C., Aubin, A., & Loomba, R. S. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01383-7 · Cited by 253
Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes
The GRADE Study Research Group (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200433 · Cited by 222
Chinese Stroke Association guidelines for clinical management of ischaemic cerebrovascular diseases: executive summary and 2023 update
Liu, L., Li, Z., Zhou, H., Duan, W., Huo, X., Xu, W., Li, S., Nie, X., Liu, H., Liu, J., et al. (2023) · Stroke and Vascular Neurology · doi:10.1136/svn-2023-002998 · Cited by 227
Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 10th edition
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Mokrysheva, N. G., Vikulova, O. K., Galstyan, G. R., Кураева, Т. Л., Peterkova, V. A., Smirnova, O. M., Starostina, E. G., et al. (2022) · Diabetes Mellitus · doi:10.14341/dm12802 · Cited by 261
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00367-2 · Cited by 193
Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England
Khunti, K., Knighton, P., Zaccardi, F., Bakhai, C., Barron, E., Holman, N., Kar, P. S., Meace, C., Sattar, N. A., Sharp, S. J., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00050-4 · Cited by 190
Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
Winiarska, A., Knysak, M., Nabrdalik, K., Gumprecht, J., & Stompór, T. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910822 · Cited by 198
Should metformin remain the first-line therapy for treatment of type 2 diabetes?
Baker, C., Retzik-Stahr, C., Singh, V., Plomondon, R., Anderson, V., & Rasouli, N. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820980225 · Cited by 204
Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis
Tsapas, A., Karagiannis, T., Kakotrichi, P., Avgerinos, I., Mantsiou, C., Tousinas, G., Manolopoulos, A., Liakos, A., Malandris, K., Matthews, D. R., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14451 · Cited by 179
Type 2 Diabetes Mellitus: A Comprehensive Review of Pathophysiology, Comorbidities, and Emerging Therapies
Singh, A. P., Shadangi, S., Gupta, P. K., & Rana, S. (2025) · Comprehensive physiology · doi:10.1002/cph4.70003 · Cited by 201
Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes
Wright, A. K., Carr, M., Kontopantelis, E., Leelarathna, L., Thabit, H., Emsley, R., Buchan, I. E., Mamas, M. A., van Staa, T. P., Sattar, N. A., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1113 · Cited by 172
Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline
Navaneethan, S. D., Zoungas, S., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Liew, A., Michos, E. D., Olowu, W. A., Sadusky, T., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-5938 · Cited by 171
Self-citation
Glycemia reduction in type 2 diabetes–microvascular and cardiovascular outcomes
The GRADE Study Research Group (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200436 · Cited by 159
Guideline recommendations and the positioning of newer drugs in type 2 diabetes care
Marx, N., Davies, M. J., Grant, P. J., Mathieu, C., Petrie, J. R., Cosentino, F., & Buse, J. B. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30343-0 · Cited by 160
Self-citation
The Current and Potential Therapeutic Use of Metformin—The Good Old Drug
Drzewoski, J., & Hanefeld, M. (2021) · Pharmaceuticals · doi:10.3390/ph14020122 · Cited by 173
A review of GLP‐1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once‐weekly agents
Cornell, S. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13230 · Cited by 156
Pharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 173
Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study
Simms-Williams, N., Treves, N., Yin, H., Lu, S., Yu, O., Pradhan, R., Renoux, C., Suissa, S., & Azoulay, L. (2024) · BMJ · doi:10.1136/bmj-2023-078242 · Cited by 151
Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus
Lee, J., Yun, J., & Ko, S. (2022) · Nutrients · doi:10.3390/nu14153086 · Cited by 161
Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial
Saxena, A. R., Frias, J. P., Brown, L. S., Gorman, D. N., Vasas, S., Tsamandouras, N., & Birnbaum, M. J. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.14493 · Cited by 149
GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis
Karagiannis, T., Tsapas, A., Athanasiadou, E., Avgerinos, I., Liakos, A., Matthews, D. R., & Bekiari, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108737 · Cited by 146
Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
Shu, Y., He, X., Wu, P., Liu, Y., Ding, Y., & Zhang, Q. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.996179 · Cited by 145
Retrospective nationwide study on the trends in first‐line antidiabetic medication for patients with type 2 diabetes in Japan
Bouchi, R., Sugiyama, T., Goto, A., Imai, K., Ihana‐Sugiyama, N., Ohsugi, M., Yamauchi, T., Kadowaki, T., & Ueki, K. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13636 · Cited by 140
Epidemiology of Diabetes and Atherosclerotic Cardiovascular Disease Among Asian American Adults: Implications, Management, and Future Directions: A Scientific Statement From the American Heart Association
Kwan, T., Wong, S. S., Hong, Y., Kanaya, A. M., Khan, S. S., Hayman, L. L., Shah, S. H., Welty, F. K., DEEDWANIA, P. C., Khaliq, A., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001145 · Cited by 140
C‐peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective
Maddaloni, E., Bolli, G. B., Frier, B. M., Little, R. R., Leslie, R. D., Pozzilli, P., & Buzzetti, R. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14785 · Cited by 135
Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial
Lam, C. S. P., Ramasundarahettige, C., Branch, K. R. H., Sattar, N., Rosenstock, J., Pratley, R., Del Prato, S., Lopes, R. D., Niemoeller, E., Khurmi, N. S., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.057934 · Cited by 132
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
Bu, T., Sun, Z., Pan, Y., Deng, X., & Yuan, G. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0277 · Cited by 131
Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
Trujillo, J. M. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13225 · Cited by 134
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial
Aroda, V. R., Aberle, J., Bardtrum, L., Christiansen, E., Knop, F. K., Gabery, S., Pedersen, S. D., & Buse, J. B. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01127-3 · Cited by 126
Self-citation
The interplay between diabetes mellitus and menopause: clinical implications
Lambrinoudaki, I. V., Paschou, S. Α., Armeni, E., & Goulis, D. G. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00708-0 · Cited by 131
Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults
Patorno, E., Pawar, A., Bessette, L. G., Kim, D. H., Dave, C. V., Glynn, R. J., Munshi, M. N., Schneeweiß, S., Wexler, D. J., & Kim, S. C. (2021) · Diabetes Care · doi:10.2337/dc20-1464 · Cited by 123
Self-citation
SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits
Marilly, E., Cottin, J., Cabrera, N., Cornu, C., Boussageon, R., Moulin, P., Lega, J., Gueyffier, F., Cucherat, M., & Grenet, G. (2022) · Diabetologia · doi:10.1007/s00125-022-05773-8 · Cited by 127
Management of post‐transplant diabetes: immunosuppression, early prevention, and novel antidiabetics
Hecking, M., Sharif, A., Eller, K., & Jenssen, T. G. (2020) · Transplant International · doi:10.1111/tri.13783 · Cited by 115
Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
Nauck, M. A., & Quast, D. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645566 · Cited by 118
Advances in multi-omics study of biomarkers of glycolipid metabolism disorder
Fang, X., Miao, R., Wei, J., Wu, H., & Tian, J. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.10.030 · Cited by 120
A Primary Care Agenda for Brain Health: A Scientific Statement From the American Heart Association
Lazar, R. M., Howard, V. J., Kernan, W. N., Aparicio, H. J., Levine, D. A., Viera, A. J., Jordan, L. C., Nyenhuis, D. L., Possin, K. L., Sorond, F. A., et al. (2021) · Stroke · doi:10.1161/str.0000000000000367 · Cited by 109
MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy
Xian, Y., Weng, J., & Xu, F. L. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001263 · Cited by 111
An AI Dietitian for Type 2 Diabetes Mellitus Management Based on Large Language and Image Recognition Models: Preclinical Concept Validation Study
Sun, H., Zhang, K., Gu, Q., Jiang, G., Yang, X., Qin, W., Qin, W., & Han, D. (2023) · Journal of Medical Internet Research · doi:10.2196/51300 · Cited by 108
Diabetic ketoacidosis with SGLT2 inhibitors
Musso, G., Saba, F., Cassader, M., & Gambino, R. (2020) · BMJ · doi:10.1136/bmj.m4147 · Cited by 109
Sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease
Patorno, E., Htoo, P. T., Glynn, R. J., Schneeweiss, S., Wexler, D. J., Pawar, A., Bessette, L. G., Chin, K., Everett, B. M., & Kim, S. C. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0893 · Cited by 103
Self-citation
Therapeutic Manipulation of Myocardial Metabolism
Honka, H., Solis‐Herrera, C., Triplitt, C. L., Norton, L., Butler, J., & DeFronzo, R. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.057 · Cited by 101
Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA 1c Levels
D’Andrea, E., Wexler, D. J., Kim, S. C., Paik, J. M., Alt, E. M., & Patorno, E. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.6664 · Cited by 105
Self-citation
Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
Ceriello, A., Catrinoiu, D., Chandramouli, C., Cosentino, F., Dombrowsky, A. C., Itzhak, B., Lalic, N. M., Prattichizzo, F., Schnell, O., Seferovic, P. M., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01408-1 · Cited by 110
Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025
Roeb, E., Canbay, A. E., Tacke, F., Bantel, H., Bojunga, J., de Laffolie, J., Demir, M., Denzer, U. W., Geier, A., Hofmann, W. P., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2283 · Cited by 108
Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
Yoneda, M., Honda, Y., Ogawa, Y., Kessoku, T., Kobayashi, T., Imajo, K., Ozaki, A., Nogami, A., Taguri, M., Yamanaka, T., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001990 · Cited by 100
Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes
Overgaard, R. V., HERTZ, C. L., Ingwersen, S. H., Navarria, A., & Drucker, D. J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100387 · Cited by 103
Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta‐analysis
Mantsiou, C., Karagiannis, T., Kakotrichi, P., Malandris, K., Avgerinos, I., Liakos, A., Tsapas, A., & Bekiari, E. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14108 · Cited by 98
The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
Li, C., Jie, L., Jiang, M., & Wang, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.838277 · Cited by 102
Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19
Lalau, J., Al‐Salameh, A., Hadjadj, S., Goronflot, T., Wiernsperger, N. F., Pichelin, M., Allix, I., Amadou, C., Bourron, O., Duriez, T., et al. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.101216 · Cited by 98
Diabetes: From Research to Clinical Practice
Islam, M. S. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_553 · Cited by 94
Addressing Therapeutic Inertia in 2020 and Beyond: A 3-Year Initiative of the American Diabetes Association
Gabbay, R. A., Kendall, D., Beebe, C., Cuddeback, J. K., Hobbs, T. M., Khan, N. D., Leal, S., Miller, E. M., Novak, L. M., Rajpathak, S. N., et al. (2020) · Clinical Diabetes · doi:10.2337/cd20-0053 · Cited by 91
Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era
Ceriello, A., Standl, E., Catrinoiu, D., Itzhak, B., Lalic, N. M., Rahelić, D., Schnell, O., Škrha, J., & Valensi, P. E. (2020) · Diabetes Care · doi:10.2337/dc20-0941 · Cited by 88
Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study
Boye, K. S., Ross, M., Mody, R., Кониг, М., & Gelhorn, H. L. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14244 · Cited by 92
Managing obesity in people with type 2 diabetes
Grant, B., Sandelson, M., Agyemang-Prempeh, B., & Zalin, A. (2021) · Clinical Medicine · doi:10.7861/clinmed.2021-0370 · Cited by 104
First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: A Cost-Effectiveness Study
Choi, J. G., Winn, A. N., Skandari, M. R., Franco, M. I., Staab, E. M., Alexander, J., Wan, W., Zhu, M., Huang, E. S., Philipson, L., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m21-2941 · Cited by 87
Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies
Bernardo, M., Rico‐Villademoros, F., García‐Rizo, C., Rojo, R., & Gómez‐Huelgas, R. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01689-8 · Cited by 92
Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
Arnold, S. V., Tang, F., Cooper, A., Chen, H., Gomes, M. B., Rathmann, W., Shimomura, I., Vora, J., Watada, H., Khunti, K., et al. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01026-2 · Cited by 86
Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement
Romeo, S., Vidal‐Puig, A., Husain, M., Ahima, R. S., Arca, M., Bhatt, D. L., Diehl, A. M., Fontana, L., Foo, R., Frühbeck, G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf314 · Cited by 93
Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study
Brand, K. M. G., Saarelainen, L., Sõnajalg, J., Boutmy, E., Foch, C., Vääräsmäki, M., Morin-Papunen, L. C., Schlachter, J., CLUE Study Group, Hakkarainen, K. M., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002363 · Cited by 94
Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
Suzuki, Y., Kaneko, H., Okada, A., Itoh, H., Matsuoka, S., Fujiu, K., Michihata, N., Jo, T., Takeda, N., Morita, H., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01508-6 · Cited by 81
The trials and tribulations of determining HbA1c targets for diabetes mellitus
Klein, K. R., & Buse, J. B. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00425-6 · Cited by 91
Self-citation
Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension
Kasiakogias, A., Rosei, E. A., Camafort, M., Ehret, G., Faconti, L., Ferreira, J. P., Brguljan-Hitij, J., Januszewicz, A., Kahan, T., Manolis, A. J., et al. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002910 · Cited by 81
Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease
Nee, R., Yuan, C. M., Narva, A. S., Yan, G., & Norris, K. C. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac283 · Cited by 83
Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease
Morales, J., & Handelsman, Y. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.052 · Cited by 86
A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study
Hiruma, S., Shigiyama, F., Hisatake, S., Mizumura, S., Shiraga, N., Hori, M., Ikeda, T., Hirose, T., & Kumashiro, N. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01228-3 · Cited by 80
Enhancement of the Performance of Large Language Models in Diabetes Education through Retrieval-Augmented Generation: Comparative Study
Wang, D., Liang, J., Ye, J., Li, J., Li, J., Zhang, Q., Hu, Q., Pan, C., Wang, D., Liu, Z., et al. (2024) · Journal of Medical Internet Research · doi:10.2196/58041 · Cited by 76
Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
Almandoz, J. P., Lingvay, I., Morales, J., & Campos, C. (2020) · Clinical Diabetes · doi:10.2337/cd19-0100 · Cited by 74
2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 81
From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
Mosenzon, O., Prato, S. D., Schechter, M., Leiter, L. A., Ceriello, A., DeFronzo, R. A., & Raz, I. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01281-y · Cited by 72
Cognitive Impairment in Frail Hypertensive Elderly Patients: Role of Hyperglycemia
Mone, P., Gambardella, J., Pansini, A., Donato, A. D., Martinelli, G., Boccalone, E., Matarese, A., Frullone, S., & Santulli, G. (2021) · Cells · doi:10.3390/cells10082115 · Cited by 72
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial
Rossing, P. R., Agarwal, R., Anker, S. D., Filippatos, G. S., Pitt, B., Ruilope, L. M., Amod, A., Marre, M., Joseph, A., Lage, A. Z., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14558 · Cited by 73
Self-citation
Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of cardiovascular outcome trials.
Patoulias, D. I., Boulmpou, A., Teperikidis, E., Katsimardou, A., Siskos, F., Doumas, M., Papadopoulos, C. E., & Vassilikos, V. (2021) · World Journal of Cardiology · doi:10.4330/wjc.v13.i10.585 · Cited by 70
Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide
Gallwitz, B., & Giorgino, F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645507 · Cited by 70

Authors: Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J.
Affiliations: University of North Carolina at Chapel Hill (US)
Harvard University (US)
Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece
University of Copenhagen (DK)
Università Cattolica del Sacro Cuore (IT)
Universitair Ziekenhuis Leuven (BE)
Duke University (US)
University of Leicester (GB)
Corresponding author: Davies, Melanie J.
ORCID: Buse, John B.
Wexler, Deborah J.
Tsapas, Apostolos
Rossing, Peter
Mingrone, Geltrude
Mathieu, Chantal
D’Alessio, David A.
Davies, Melanie J.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2019-12-19
Volume: 43
Issue: 2
Pages: 487-493
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/dci19-0066
PMC: PMC6971782
OpenAlex: W4253996779
Cited by: 1,192
References: 21
Citations by year: 2026: 54 · 2025: 79 · 2024: 128 · 2023: 162 · 2022: 277 · 2021: 279 · 2020: 212
FWCI: 155.76
Type: journal article
Language: en
Update notices: correction (2020-07-01)
Open access: bronze
doi.org
Licence: www.diabetesjournals.org/content/license (vor, 32 d)
Locations: Diabetes Care (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
Lirias (submittedVersion)
PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
Funders: American Diabetes Association
European Association for the Study of Diabetes
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords: hyperglycemia management, type 2 diabetes, GLP-1 receptor agonists, SGLT2 inhibitors, major adverse cardiovascular events, heart failure hospitalization, heart failure with reduced ejection fraction, chronic kidney disease progression, HbA1c targets, cardiovascular risk stratification

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks